SCT 520FF
Alternative Names: SCT-520FF; VEGF FabLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Sinocelltech
- Class Eye disorder therapies; Fab fragments
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 04 Nov 2024 Sinocelltech Ltd plans phase-I/II trial for Wet-age related macular degeneration (In adults, In the elderly) in November 2024 (Intravitreal, Injection) (NCT06672536)
- 22 Feb 2021 Preclinical trials in Wet age-related macular degeneration in China (unspecified route) before February 2021 (Sinocelltech pipeline, February 2021)